Please use this identifier to cite or link to this item: 10.1530/EJE-20-0204
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCastellana, Marco-
dc.contributor.authorGrani, Giorgio-
dc.contributor.authorRadzina, Maija-
dc.contributor.authorGuerra, Vito-
dc.contributor.authorGiovanella, Luca-
dc.contributor.authorDeandrea, Maurilio-
dc.contributor.authorNgu, Rose-
dc.contributor.authorDurante, Cosimo-
dc.contributor.authorTrimboli, Pierpaolo-
dc.date.accessioned2022-08-16T21:00:55Z-
dc.date.available2022-08-16T21:00:55Z-
dc.date.issued2020-09-
dc.identifier.citationCastellana , M , Grani , G , Radzina , M , Guerra , V , Giovanella , L , Deandrea , M , Ngu , R , Durante , C & Trimboli , P 2020 , ' Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules : A meta-analysis ' , European Journal of Endocrinology , vol. 183 , no. 3 , pp. 255-264 . https://doi.org/10.1530/EJE-20-0204-
dc.identifier.issn0804-4643-
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/9359-
dc.descriptionPublisher Copyright: © 2020 European Society of Endocrinology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.-
dc.description.abstractObjective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions.en
dc.format.extent10-
dc.format.extent1058206-
dc.language.isoeng-
dc.relation.ispartofEuropean Journal of Endocrinology-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subject3.2 Clinical medicine-
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database-
dc.subjectEndocrinology, Diabetes and Metabolism-
dc.subjectEndocrinology-
dc.subjectSDG 3 - Good Health and Well-being-
dc.titlePerformance of EU-TIRADS in malignancy risk stratification of thyroid nodules : A meta-analysisen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article-
dc.identifier.doi10.1530/EJE-20-0204-
dc.contributor.institutionDepartment of Radiology-
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85088846666&partnerID=8YFLogxK-
dc.description.statusPeer reviewed-
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:
File SizeFormat 
Performance_of_EU_TIRADS.pdf1.03 MBAdobe PDFView/Openopen_acces_unlocked


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.